Login
Merck & Company NYSE: MRK
Merck & Co., Inc. provides healthcare solutions worldwide in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.
| Name | Merck & Company |
| Ticker | MRK |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
|
Price
52W Low/High |
72.62
66.40 / 86.93 |
| Momentum | Weak Down |
| Market cap | 184 B |
| 1Y Total Return |
-1.91%
Weak |
| 1Y Volatility |
31.88%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Merck & Co., Inc. provides healthcare solutions worldwide in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.
Details
| Ticker | MRK |
| Name | Merck & Company |
| ISIN | US58933Y1055 |
| CUSIP | 58933Y105 |
| Exchange | NYSE |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 2/26/21
| Close Price | 72.62 |
| 52W Low/High | 66.40 / 86.93 |
| Market cap | 184 B |
| 1Y Total Return |
-1.91%
Weak |
| 1Y Volatility |
31.88%
Low Risk |
| Beta | 0.98 |
| PE (trailing) |
16.07
Below Average |
| 12M Dividends | 2.44 |
| Last Dividend Date | 12/14/20 |
| Dividend Yield | 3.36% |
Fin. Strength
| Net Profit Margin | 24.3% |
| Cash from Op. / Cur. Liabilities | 0.54 |
| Diluted Earnings / Share | 4.52 |
| ROE | 41.1% |
| ROIC | 19.1% |
| Price / Revenue | - |
| Price / Book | - |
| Price / CF | - |
| Current Ratio | 1.3 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.98 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
47,348
|
45,971
|
41,729
|
39,804
|
39,907
|
39,765
|
|
| Gross Profit |
33,727
|
32,239
|
28,069
|
26,861
|
25,498
|
24,932
|
|
| R&D |
10,270
|
9,538
|
9,853
|
12,811
|
7,272
|
7,190
|
|
| EBITDA |
17,214
|
15,113
|
12,633
|
7,957
|
12,659
|
22,762
|
|
| Operating Income |
12,722
|
11,750
|
7,315
|
3,036
|
7,823
|
6,385
|
|
| Net Income exc. Extra |
11,518
|
9,313
|
3,347
|
2,846
|
5,491
|
10,782
|
|
| per Share | |||||||
| Diluted avg Shares |
-
|
-
|
-
|
-
|
-
|
-
|
|
| EPS exc. Extra |
4.52
|
3.58
|
1.25
|
1.04
|
1.95
|
3.71
|
|
| Dividend |
2.44
|
2.20
|
1.92
|
1.88
|
1.84
|
1.80
|
|
| Div. Yield (an.) |
2.94%
|
2.61%
|
2.71%
|
2.94%
|
2.95%
|
3.64%
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
89,800
|
83,331
|
85,130
|
91,676
|
98,335
|
101,232
|
|
| Cash, Eq & Invt ShortTerm |
7,356
|
8,018
|
10,285
|
11,195
|
13,067
|
12,089
|
|
| Total Current Assets |
26,577
|
26,142
|
26,836
|
27,919
|
29,440
|
28,567
|
|
| Total Non-Current Assets |
63,223
|
57,189
|
58,294
|
63,757
|
68,895
|
72,665
|
|
| Intangibles |
36,925
|
31,787
|
30,433
|
33,478
|
38,766
|
41,485
|
|
| Total Liabilities |
60,530
|
56,406
|
52,474
|
53,177
|
54,378
|
55,553
|
|
| Total Current Liabilities |
20,405
|
20,684
|
18,586
|
19,467
|
15,555
|
17,583
|
|
| Long Term Debt |
40,125
|
35,722
|
33,888
|
33,710
|
38,823
|
37,970
|
|
| Shareholder equity |
29,186
|
26,838
|
32,422
|
38,248
|
43,744
|
45,587
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
11,041
|
12,238
|
11,349
|
6,064
|
10,990
|
7,257
|
|
| Depreciation |
3,657
|
3,714
|
4,688
|
4,694
|
5,846
|
6,388
|
|
| Cash from Investing |
-5,428
|
312
|
2,078
|
174
|
-1,264
|
3,063
|
|
| Capex |
4,307
|
3,265
|
2,401
|
1,724
|
1,556
|
1,280
|
|
| Cash from Financing |
-6,215
|
-12,416
|
-13,379
|
-6,198
|
-9,473
|
-12,753
|
|
| Stock Issued |
-2,246
|
-9,189
|
-4,381
|
-2,698
|
-2,758
|
-4,012
|
|
| Debt (LT) Issued |
2,336
|
2,616
|
-3,503
|
1,831
|
-1,492
|
-3,495
|
|
| Free Cash Flow |
10,612
|
9,774
|
-2,086
|
9,640
|
7,426
|
851
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
24.3%
|
20.3%
|
8.0%
|
7.2%
|
13.8%
|
27.1%
|
|
| NCFO / Op.Income |
86.8%
|
104.2%
|
155.1%
|
199.7%
|
140.5%
|
113.7%
|
|
| Current Ratio |
1.3
|
1.3
|
1.4
|
1.4
|
1.9
|
1.6
|
|
| Financial Leverage D/E |
0.98
|
0.97
|
0.73
|
0.71
|
0.57
|
0.58
|
|
| Return on Capital Avg |
19.1%
|
14.8%
|
-5.3%
|
4.4%
|
8.3%
|
3.7%
|
|
| Return on Shareholder Equity |
41.1%
|
31.4%
|
9.5%
|
6.9%
|
12.3%
|
23.7%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available